Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.55 |
| ▸ | MAOB | P27338 | 5/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | CALML3 | P27482 | 1/20 | 0.55 |
| ▸ | SDHA | P31040 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3140943 | 0.92 | F10 (0.55) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL3155845 | 0.91 | F10 (0.66) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL3151580 | 0.89 | F10 (0.67) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL3142181 | 0.89 | F10 (0.54) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL3150504 | 0.88 | F10 (0.62) | F10 | |
| SCHEMBL3154882 | 0.87 | F10 (0.67) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL3155676 | 0.85 | F10 (0.56) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL3151478 | 0.84 | F10 (0.58) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL3150332 | 0.83 | F10 (0.54) | F10 | |
| SCHEMBL3160314 | 0.83 | F10 (0.51) | F10MAOBMAOALMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1526132-B1 | Substituted oxazolidinone derivatives and their use as factor xa inhibitors | BAYER IP GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| EP-1411932-B1 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | BAYER SCHERING PHARMA AG (DE) | 2010-02-10 | — | — | EP | disclosed |
| EP-2099453-A2 | COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-09-16 | — | — | EP | disclosed |
| EP-1937271-A1 | MICROANGIOPATHY TREATMENT AND PREVENTION | Bayer HealthCare AG (DE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008052671-A2 | COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-08 | — | — | WO | disclosed |
| WO-2007042146-A1 | MICROANGIOPATHY TREATMENT AND PREVENTION | BAYER HEALTHCARE AG (DE) | 2007-04-19 | — | — | WO | disclosed |
| EP-1526132-A2 | Substituted oxazolidinone derivatives and their use as factor xa inhibitors | Bayer HealthCare AG (DE) | 2005-04-27 | — | — | EP | disclosed |
| EP-1261606-B1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER HEALTHCARE AG (DE) | 2005-02-23 | — | — | EP | disclosed |
| EP-1411932-A1 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | Bayer HealthCare AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003000256-A9 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | BAYER AG (DE) | 2003-02-06 | — | — | WO | disclosed |
| WO-2003000256-A1 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | BAYER HEALTHCARE AG (DE) | 2003-01-03 | — | — | WO | disclosed |
| WO-2001047919-A9 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER AG (DE) | 2002-12-19 | — | — | WO | disclosed |
| EP-1261606-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | Bayer Aktiengesellschaft (DE) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001047919-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-05 | — | — | WO | disclosed |